Thymoma Clinical Trial
Official title:
Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin combined with paclitaxel in treating patients who have advanced thymoma.
OBJECTIVES: - Determine the objective response rate in patients with advanced thymoma or thymic carcinoma treated with carboplatin and paclitaxel. - Determine the duration of response in these patients treated with this regimen. - Determine the toxicity of this regimen in these patients. OUTLINE: Patients receive paclitaxel by intravenous (IV) infusion over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression. Patients achieving complete or partial remission or stable disease receive 4 additional courses of therapy for a maximum of 6 courses. Further treatment may be given at the discretion of the treating physician. Patients were followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 35-68 patients were to be accrued for this study within 3.8-4.6 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
| Terminated |
NCT00818090 -
Paclitaxel and Cisplatin for Thymic Neoplasm
|
Phase 2 | |
| Completed |
NCT00332969 -
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
|
Phase 2 | |
| Completed |
NCT00921739 -
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
|
Phase 1 | |
| Recruiting |
NCT05255965 -
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
|
||
| Withdrawn |
NCT02948855 -
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
|
||
| Completed |
NCT00387868 -
Preoperative Treatment of Patients With High Risk Thymoma
|
Phase 2 | |
| Completed |
NCT01272817 -
Nonmyeloablative Allogeneic Transplant
|
N/A | |
| Recruiting |
NCT03466827 -
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
|
Phase 2 | |
| Completed |
NCT02220855 -
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
|
Phase 2 | |
| Completed |
NCT03288662 -
Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors
|
N/A | |
| Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 | |
| Recruiting |
NCT06029621 -
Robot-assisted vs VATS for Thymoma
|
N/A | |
| Active, not recruiting |
NCT03921671 -
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
|
Phase 2 | |
| Active, not recruiting |
NCT01621568 -
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
|
Phase 2 | |
| Recruiting |
NCT05262582 -
Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy
|
N/A | |
| Terminated |
NCT01100944 -
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03968315 -
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
|
N/A | |
| Recruiting |
NCT04162691 -
Single Cell Sequencing Analysis of Thymoma
|
||
| Recruiting |
NCT06086327 -
Application of 68Ga-Pentixafor PET/CT for Thymoma
|
Early Phase 1 |